Procalcitonin and C-reactive protein serum levels as markers of infection in a pediatric population with febrile neutropenia and cancer

Pediatric Hematology and Oncology

Volumn 26, Issue 6, 2009, Pages 414-425

  Martinez Albarran, Manuel ^a   Perez Molina, Jose De Jesus ^a   Gallegos Castorena, Sergio ^a   Sanchez Zubieta, Fernando ^a   Del Toro Arreola, Susana ^b   Troyo Sanroman, Rogelio ^b   Gonzalez Ramella, Oscar ^a  

^a HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

C reactive protein; Febrile neutropenia; Infection marker; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

ARTICLE; BACTERIAL INFECTION; BLOOD LEVEL; CANCER PATIENT; CHILD; CHILDHOOD CANCER; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; SCREENING TEST; SENSITIVITY ANALYSIS; SEPSIS;

ADOLESCENT; BACTERIA; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEXICO; NEOPLASMS; NEUTROPENIA; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 68649107118     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010903044797     Document Type: Article

References (31)

1. Slats AM, Egeler RM, Van Der Does-van den Berg A, et al. Causes of death - other than progressive leukemia - in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia. 2005;19:537-544.
2. Rubnitz JE, Lensing S, Zhou Y, et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer. 2004;101:1677-1684. (Pubitemid 39318917)
3. Armendariz H, Barbieri MA, Freigeiro D, et al. Treatment strategy and long-term results in pediatric patients treated in two consecutive AML-GATLA trials. Leukemia. 2005;19:2139-2142. (Pubitemid 41741606)
4. Lacour AG, Gervaix A, Zamora SA, et al. Procalcitonin, IL-6, IL-8, IL-1 receptor antagonist and C-reactive protein as identificators of serious bacterial infections in children with fever without localising signs. Eur J Pediatr. 2001;160:95-100. (Pubitemid 32204534)
5. Galetto-Lacour A, Zamora SA, et al. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics. 2003;112:1054-1060. (Pubitemid 37339556)
6. Putto A, Ruuskanen O, Meurman O, et al. C reactive protein in the evaluation of febrile illness. Arch Dis Child. 1986;61:24-29. (Pubitemid 16124845)
7. Buchanan GR. Approach to treatment of the febrile cancer patient with low-risk neutropenia. Hematol Oncol Clin North Am. 1993;7:919-935. (Pubitemid 23294237)
8. Mendes AV, Sapolnik R, Mendonca N. New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients. J Pediatr (Rio J). 2007;83:S54-63. (Pubitemid 46920392)
9. Santolaya ME, Alvarez AM, Aviles CL, et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol. 2004;22:3784-3789.
10. Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol. 2001;19:3415-3421. (Pubitemid 32642195)
11. Santolaya ME, Alvarez AM, Aviles CL, et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clin Infect Dis. 2002;35:678-683.
12. Klaassen RJ, Goodman TR, Pham B, et al. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000;18:1012-1019. (Pubitemid 30123777)
13. Rondinelli PI, Ribeiro Kde C, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol. 2006;28:665-670.
14. Santolaya ME, Rabagliati R, Bidart T, et al. [Consensus: Rational approach towards the patient with cancer, fever and neutropenia]. Rev Chilena Infectol. 2005;22(Suppl 2):S79-S113.
15. Barnes C, Ignjatovic V, Newall F, et al. Change in serum procalcitonin (deltaPCT) predicts the clinical outcome of children admitted with febrile neutropenia. Br J Haematol. 2002;118:1197-1198. (Pubitemid 35025997)
16. Gendrel D, Bohuon C. Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J. 2000;19:679-687; quiz 688.
17. van Rossum AM, Wulkan RW, Oudesluys-Murphy AM. Procalcitonin as an early marker of infection in neonates and children. Lancet Infect Dis. 2004;4:620-630. (Pubitemid 39296836)
18. Fleischhack G, Kambeck I, Cipic D, et al. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol. 2000;111:1093-1102. (Pubitemid 32104921)
19. Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, et al. Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect. 2004;10:628-633. (Pubitemid 39077050)
20. Massaro KS, Costa SF, Leone C, et al. Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis. 2007;7:137. (Pubitemid 351193974)
21. El-Maghraby SM, Moneer MM, Ismail MM, et al. The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies. J Pediatr Hematol Oncol. 2007;29:131-136.
22. Stabell N, Nordal E, Stensvold E, et al. Febrile neutropenia in children with cancer: a retrospective Norwegian multicentre study of clinical and microbiological outcome. Scand J Infect Dis. 2008;40:301-307.
23. Courtney DM, Aldeen AZ, Gorman SM, et al. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist. 2007;12:1019-1026.
24. Mitchell PL, Morland B, Stevens MC, et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol. 1997;15:1163-1170. (Pubitemid 27106304)
25. Ozkaynak MF, Krailo M, Chen Z, Feusner J. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2005;45:274-280. (Pubitemid 41077160)
26. Tezcan G, Kupesiz A, Ozturk F, et al. Episodes of fever and neutropenia in children with cancer in a tertiary care medical center in Turkey. Pediatr Hematol Oncol. 2006;23:217-229. (Pubitemid 43361804)
27. Secmeer G, Devrim I, Kara A, et al. Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia. J Pediatr Hematol Oncol. 2007;29:107-111. (Pubitemid 46213857)
28. Uys A, Rapoport BL, Fickl H, et al. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care (Engl). 2007;16:475-483.
29. Erten N, Genc S, Besisik SK, et al. The predictive and diagnostic values of procalcitonin and C-reactive protein for clinical outcome in febrile neutropenic patients. J Chin Med Assoc. 2004;67:217-221. (Pubitemid 39069701)
30. Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, et al. Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis. 2001;32:1718-1725. (Pubitemid 32532002)
31. Engel A, Steinbach G, Kern P, et al. Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis. 1999;31:185-189. (Pubitemid 29355529)